Takeda Business Division’s Masato Iwasaki: We Will Not Join Promotion Of SGLT-2 Inhibitors
This article was originally published in PharmAsia News
Takeda does not plan to join in the promotional activities of SGLT-2 inhibitors despite the expected approval of its own oral hypoglycemic SGLT-2 inhibitor in 2014, the company’s Business Division Head Masato Iwasaki said Nov. 20.
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.